Developmentandintroduction of internaltechnicaldocumentation, alongwiththeprocedures and processesnecessary togeneratethosedocuments, andmanage changestothem.
Instead, again with data as crystal clear as an azure sky of deepest blue, the report identifies potential root causes in intellectual property, business practice and unforeseen technical challenges as playing a significant role, alongwith some areas where the FDA could help foster drug development.